BioSpace News Archive

Novo Nordisk today announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th Scientific Sessions of the American Diabetes Association (ADA).

Assembly Biosciences, Inc. announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a next-generation capsid assembly modulator candidate in development for the treatment of chronic hepatitis B virus infection.

Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA® is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds.

FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET.

Aquestive Therapeutics, Inc. announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024.

CorMedix Inc. announced that the U.S. Food and Drug Administration has provided feedback to the Company’s request to discuss development plans for additional indications for DefenCath.

Annexon, Inc. today announced the Company will have several presentations on the Company’s ANX005 Guillain-Barré Syndrome (GBS) program at the 2024 Peripheral Nerve Society (PNS) Annual Meeting being held June 22-25, 2024 at the Palais des congrès de Montréal in Montréal, Canada.

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as MSD outside the United States and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE.

Aytu BioPharma, Inc. today announced the successful refinancing of its existing term loan and extension of its revolving credit facility on more favorable terms to the Company.

Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).